Survodutide vs Tirzepatide: differences, evidence and safety

Answer first

Survodutide switches on the receptors for GLP-1 and glucagon and is an experimental drug in phase 3, approved nowhere. Tirzepatide switches on the receptors for GIP and GLP-1 and is an approved prescription medicine. No study comparing the two directly could be found, so the figures below come from separate trials and cannot be ranked.

At a glance

How they work

Both drugs are laboratory-made peptides that act on two hormone docking points, or receptors, at once. Survodutide is a chain of 29 amino acids; tirzepatide is a chain of 39 ^[1], ^[2]. Survodutide was discovered by Zealand Pharma and is being developed by Boehringer Ingelheim ^[3]. Tirzepatide comes from Eli Lilly ^[2].

Survodutide

• The GLP-1 half. It slows the emptying of the stomach, curbs appetite and prompts insulin release only when blood sugar is high ^[4].
• The glucagon half. Glucagon signalling raises the energy the body burns and mobilises fat stored in the liver ^[5], ^[4].
• Part of the liver effect may not run through weight loss. In a phase 2 analysis, weight loss explained 71.8 per cent of the effect on liver inflammation but only 36.3 per cent of the effect on scarring ^[6].

Tirzepatide

• The GIP half. Its chain copies the gut hormone GIP (glucose-dependent insulinotropic polypeptide) and switches on that receptor. How much this half contributes by itself is not settled ^[2].
• The GLP-1 half. Switching on this receptor slows the stomach and makes people eat less ^[2].
• Insulin and glucagon. According to the label, the body releases more insulin and less glucagon, but only when blood sugar is high ^[2].

The core difference is the partner of GLP-1. Tirzepatide combines two gut hormones. The glucagon receptor is not a gut hormone receptor, so the two mechanisms are not interchangeable ^[5]. According to its label, tirzepatide lowers glucagon release; survodutide instead switches the glucagon receptor on ^[2], ^[5].

Both carry a fatty acid chain that binds to proteins in the blood and slows removal. The body takes about five days to clear half a dose of tirzepatide ^[2]. For survodutide, no half-life figure could be found in the published record reviewed ^[5].

What the studies show

No study that compares survodutide and tirzepatide directly could be found in the published record reviewed for this page. For survodutide, the only direct comparison with another drug in people that could be found is an open-label semaglutide arm in a phase 2 trial ^[7].

Everything below therefore comes from separate trials. They enrolled different people, gave different doses, measured different endpoints and ran for different lengths of time. Their numbers cannot be set against each other. Two survodutide trials were analysed with two statistical rules. This page leads with the one that counts everyone randomised, including people who stopped early ^[8], ^[3].

Weight in adults without diabetes

Phase 3 RCT SURMOUNT-1 allocated 2,539 adults with obesity and without diabetes at random to tirzepatide or to a dummy injection, and followed them for 72 weeks. Average weight fell by 15.0%, 19.5% and 20.9% across the three doses tested, against 3.1% on placebo ^[9].

Phase 3 RCT SYNCHRONIZE-1 randomised 725 adults with obesity and without diabetes to two survodutide dose levels or placebo. After 76 weeks, average weight was 12.2 and 13.0 per cent below baseline, against 5.4 per cent on placebo ^[8].

Company announcement A second analysis of the same trial, announced by Zealand Pharma, estimates the effect had everyone stayed on treatment. It gives 16.6 against 3.2 per cent. Both figures are correct and answer different questions ^[8], ^[10].

Phase 2 RCT An earlier survodutide trial treated 386 adults for 46 weeks. Weight fell by 6.2, 12.5, 13.2 and 14.9 per cent across four dose levels, against 2.8 per cent on placebo. Only 233 of the 386 finished ^[11].

Weight in adults with type 2 diabetes

Phase 3 RCT SURMOUNT-2 enrolled 938 adults who had obesity together with type 2 diabetes. By week 72 the two tirzepatide groups had lost 12.8% and 14.7% of their weight, less than in people without diabetes ^[12].

No result The matching survodutide trial, SYNCHRONIZE-2, enrolled 755 people with diabetes and has ended. On 17 September 2026 the registry showed no results, and no published results could be found. Only a paper on its design has appeared ^[13].

Long-term blood sugar

Both drugs were tested on glycated haemoglobin, a blood value that reflects average blood sugar over the past two to three months.

Phase 3 RCT SURPASS-1 enrolled 478 adults with type 2 diabetes who had not yet taken any diabetes medicine. After 40 weeks the value fell by 1.87 to 2.07 percentage points from a starting level of 7.9%. On placebo it crept up by 0.04 points ^[14].

Phase 3 RCT, open-label SURPASS-2 enrolled 1,879 adults already taking metformin. The value fell by 2.01, 2.24 and 2.30 points across three tirzepatide doses, compared with 1.86 points on semaglutide ^[15].

Phase 2 RCT A 16-week survodutide trial enrolled 411 adults with type 2 diabetes, with placebo and an open semaglutide arm. From a starting value of 8.07 per cent, the value fell by between 0.91 and 1.71 percentage points ^[7]. At the lower dose levels the fall matched semaglutide, 1.46 against 1.47 percentage points ^[7].

Semaglutide appears in both programmes, but not as a bridge. The trials differ in length, phase, population and blinding, so their results cannot be chained into a ranking.

Liver

Phase 2 RCT SYNERGY-NASH treated 190 adults for 52 weeks whose fatty liver had become inflamed and scarred, confirmed by a tissue sample (fibrosis F2 or F3). Among 157 people with an assessable follow-up sample, the inflammation cleared without worse scarring in 44%, 56% and 62% on tirzepatide, against 10% on placebo ^[16].

Phase 2 RCT A survodutide trial measured the same kind of endpoint over 48 weeks. It enrolled 293 adults with biopsy-confirmed inflammation and scarring, stages F1 to F3. The endpoint was reached by 47 per cent at the lowest dose level, 62 at the middle and 43 at the highest. On placebo it was 14 per cent ^[17], ^[13].

More was not better there: the best-fitting model was a curve rather than a straight line ^[17]. Improvement of scarring by at least one stage reached 34, 36 and 34 per cent against 22 on placebo, not a primary endpoint ^[17].

Phase 3 RCT SYNCHRONIZE-MASLD treated 216 adults with obesity and fatty liver disease for 48 weeks. A cut in liver fat of at least 30 per cent, measured by scan, was reached by 68.5 against 28.6 per cent on placebo ^[3].

The two phase 2 trials enrolled different scarring stages and ran for different lengths. For both drugs, larger liver trials are still recruiting ^[18], ^[13].

Heart

Phase 3 RCT, active comparator SURPASS-CVOT followed 13,299 adults with type 2 diabetes and hardened arteries for a median of 210.1 weeks. A serious heart event occurred in 12.2% of those on tirzepatide and 13.1% on dulaglutide ^[19].

That is a risk 8% lower (hazard ratio 0.92), but the range compatible with the data, 0.83 to 1.01, included no difference. Tirzepatide was shown to be no worse than dulaglutide; being better was tested and not shown (p = 0.09) ^[19].

Phase 3 RCT SUMMIT followed 731 people with obesity and the stiff form of heart failure for a median of 104 weeks. Death from a heart cause or worsening heart failure occurred in 9.9% on tirzepatide and 15.3% on placebo ^[20].

No result SYNCHRONIZE-CVOT enrolled 5,531 adults with overweight or obesity to test survodutide's effect on heart events up to week 114. It finished on 30 June 2026. The registry shows no results, and no published results could be found; only the design and starting characteristics have appeared ^[13], ^[21].

Outcomes studied for only one of the two

• Tirzepatide and sleep apnoea. SURMOUNT-OSA enrolled 469 adults with obesity and moderate to severe obstructive sleep apnoea. By week 52 breathing interruptions fell by 20.0 and 23.8 events per hour of sleep more than on placebo ^[22].
• Tirzepatide and keeping weight off. In SURMOUNT-4, 670 people first took tirzepatide for 36 weeks. Between week 36 and week 88 those who carried on lost a further 5.5%, while those switched to placebo regained 14.0% ^[23].
• Survodutide in liver cirrhosis. A phase 1 study found that blood levels in people with cirrhosis matched those of healthy controls at every severity grade. Drug-related events affected 82.4 and 87.5 per cent of participants over 28 weeks ^[24].

Safety

The two safety records come from different kinds of source. Tirzepatide's figures come from approved US product information that pools the weight-loss trials. Survodutide has no approved product information anywhere, so its figures come from trial publications only ^[13]. The lists below are therefore not a ranking.

Tirzepatide. The pooled weight-loss trials covered 3,477 people on the drug ^[25].

• Stomach and bowel. Nausea affected 25–29% against 8% on placebo, and diarrhoea 19–23% against 8%. Vomiting affected 8–13% against 2%, and constipation 11–17% against 5% ^[25].
• Stopping treatment. Side effects led 4.8–6.7% of participants to stop, against 3.4% on placebo ^[25].
• Boxed warning. In rats, tirzepatide causes tumours in the C-cells of the thyroid gland, more often at higher doses and longer exposure. Whether this applies to people is unknown ^[2], ^[25].
• Who must not take it. People with medullary thyroid cancer, personally or in the family, or with the inherited condition multiple endocrine neoplasia type 2 ^[2], ^[25].
• Further label warnings. Pancreas inflammation, kidney damage from fluid loss, gallbladder trouble, low blood sugar alongside insulin and worsening diabetic eye disease ^[2], ^[25].

Survodutide.

• Stomach and bowel. In SYNCHRONIZE-1 such symptoms affected 80.9 and 89.7 per cent of the two treated groups, against 47.9 per cent on placebo. Most were mild or moderate ^[8].
• Single symptoms. In the phase 2 liver trial, nausea affected 66 against 23 per cent, diarrhoea 49 against 23 and vomiting 41 against 4. Serious events occurred in 8 against 7 per cent ^[17].
• Stopping treatment. Only 233 of 386 participants, or 60.4 per cent, completed the 46-week phase 2 obesity trial ^[11].
• Heart and vessels. In one early study, 10 of 80 participants withdrew, most often after a heart or vessel event, in 6 ^[4]. A review names a modest rise in heart rate, but no figures backing this could be found in the primary trial reports ^[26].
• Open questions. No regulatory assessment of survodutide could be found in the registers checked, so no risk management plan is available. Nothing published could be found on antibodies against the drug, pregnancy, breastfeeding or children ^[13].

The American medicines agency names survodutide among substances sold illegally to consumers under a research label, calling such products of unknown quality ^[27]. In August 2026 it formally warned a seller that listed it ^[28].

Why this page lists no doses. Tirzepatide is prescription-only wherever it is approved. Survodutide is an experimental drug approved nowhere, with no lawful use outside a trial. Choosing an amount is a matter for the product information and the prescribing doctor. This page therefore names doses only by their rank among those tested, not as an amount.

Legal status

Tirzepatide is an approved, prescription-only medicine in eight markets. The United States cleared it on 13 May 2022 and the European Union on 15 September 2022; the United Kingdom, Australia, Canada, Switzerland and Japan followed ^[29], ^[30], ^[31]. Survodutide is approved in no market; its European and American development designations are expressly not approvals ^[32], ^[33], ^[34], ^[35]. In sport, tirzepatide is not on the 2026 prohibited list and has been on the penalty-free monitoring programme since 1 January 2026 ^[36], ^[37]. Survodutide is banned at all times under section S0, which covers unapproved substances ^[38]. The monographs reflect the position on 6 and 17 September 2026.

Used together?

The myPeptides blend directory lists no product that contains survodutide or tirzepatide, and therefore no combination of the two.

No study of the two drugs given together could be found in the sources reviewed for this page. Survodutide has no lawful setting for use outside a clinical trial, and tirzepatide is available only on prescription ^[13], ^[29]. Both already act on the GLP-1 receptor ^[4], ^[2].

Frequently asked questions

Which is better, survodutide or tirzepatide?

The evidence does not say. In SURMOUNT-1, among 2,539 adults without diabetes, tirzepatide lowered weight by 15.0% to 20.9% over 72 weeks. Survodutide was not part of that trial; in SYNCHRONIZE-1, among 725 adults without diabetes, it lowered weight by 12.2 and 13.0 per cent over 76 weeks. No study comparing the two directly could be found.

Is survodutide or tirzepatide safer?

No study comparing their safety directly could be found. Tirzepatide's record comes from approved product information and a heart trial of 13,299 people, and it carries a boxed warning about thyroid tumours in rats. Survodutide's record comes only from trial publications, and no published result of its heart outcome trial could be found. With both, stomach and bowel complaints are the most common.

What is the difference between survodutide and tirzepatide?

Both switch on the GLP-1 receptor. Survodutide pairs it with the receptor for glucagon, the hormone that pushes blood sugar up; tirzepatide pairs it with the receptor for GIP, a second gut hormone. Tirzepatide is an approved prescription medicine in eight markets. Survodutide is an experimental drug approved in none.

Can survodutide and tirzepatide be taken together?

No study of the two drugs given together could be found in the sources reviewed, and the myPeptides blend directory lists no product containing either of them. Survodutide can lawfully be used only within a clinical trial, and tirzepatide is available only on prescription.

When will survodutide be available?

No date can be given. On 17 September 2026 survodutide was approved in no country, and no application for approval could be found in the sources reviewed. For four completed phase 3 trials, including the heart safety trial, no published results could be found. The European and American development designations speed research up but are not approvals. The large liver trial LIVERAGE is due to finish in 2031.

Is survodutide a twincretin like tirzepatide?

No. The nickname twincretin refers to combining two gut hormones, as tirzepatide does with GIP and GLP-1. The glucagon receptor that survodutide targets is not a gut hormone receptor, so the two mechanisms are not interchangeable.

Have survodutide and tirzepatide been tested against the same drug?

Yes, against semaglutide, but in separate trials. Tirzepatide was compared with it in a 40-week phase 3 trial in 1,879 adults with type 2 diabetes. Survodutide had an open semaglutide arm in a 16-week phase 2 trial in 411 adults with type 2 diabetes. The trials differ too much to link the results.

Are survodutide and tirzepatide banned in sport?

Survodutide is banned at all times under section S0, which covers substances that no health authority has approved. It is not named on the 2026 list; it falls under the ban because of its status. Tirzepatide is not on the 2026 prohibited list; it has been on the penalty-free monitoring programme since 1 January 2026.

How long do survodutide and tirzepatide stay in the body?

For tirzepatide, the body takes about five days to clear half a dose. For survodutide, no half-life figure could be found in the published record reviewed. Both carry a fatty acid chain that binds to proteins in the blood and slows their removal.